Long-term Safety and Efficacy of Tirzepatide in Type 2 Diabetes: 3-Year Follow-up Data

The New England Journal of Medicine

BPC-157 Oral Administration: Systematic Review of Bioavailability and Therapeutic Outcomes

Journal of Peptide Science

Comparative Analysis of GLP-1 Receptor Agonists: Semaglutide vs Tirzepatide in Real-World Settings

Obesity Reviews

CJC-1295/Ipamorelin Combination Therapy: Growth Hormone Secretagogue Profiles in Adult Males

Endocrine Practice

Peptide Therapy Compliance and Patient Outcomes: A Multi-Center Observational Study

Frontiers in Endocrinology

Tirzepatide continues to show remarkable weight loss results in Phase 4 trials. Patients averaging 22% body weight reduction at 72 weeks.

BPC-157 oral vs. injectable: new systematic review finds comparable bioavailability for gut-related healing. Game changer for patient compliance.

FDA just approved retatrutide for Phase 3 trials as a triple agonist (GLP-1/GIP/glucagon). This could be the next big thing after tirzepatide.

My 6-month BPC-157 + TB-500 recovery stack results are in. Full bloodwork comparison thread below.

Compounded semaglutide prices dropping across telehealth platforms. Seeing sub-$200/mo now from several providers.